Last 28 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -1.32 | — | — | — | — | — | — | — | — | — | 28.14 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | 2.01 | — | — | 6.92 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 0.84 | 2.37 | 0.90 | 0.45 | 0.43 | 0.30 | 0.39 | 0.64 | 0.74 | 0.76 | 2.45 | 2.45 | 2.94 | 3.28 | 2.64 | 2.75 | 2.87 | 3.04 | 6.61 | 10.37 | 7.55 |
| — | +679.8% | +133.3% | -30.1% | -41.7% | -59.9% | -84.2% | -73.9% | -74.9% | -76.8% | -7.5% | -10.9% | +2.4% | +7.9% | -60.0% | -73.5% | -62.0% | -65.3% | +10.5% | +66.7% | +122.4% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | 27.74 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | 100.0% | — | — | 99.2% | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | -185.6% | — | — | -61.1% | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | -176.7% | — | — | 24.8% | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -49.5% | -47.6% | -17.7% | -15.0% | -10.1% | -9.4% | -15.3% | -13.7% | -10.9% | -21.0% | 2.2% | -13.3% | -11.0% | -24.8% | -15.4% | -12.7% | -12.1% | -17.3% | -17.4% | -13.2% | -1.3% |
| — | -404.5% | -16.1% | -9.4% | +7.1% | +55.1% | -779.4% | -3.6% | +1.4% | +15.2% | +114.6% | -4.0% | +8.5% | -42.8% | +11.2% | +3.5% | -823.8% | +14.2% | -9.0% | -14.5% | +88.6% | |
| ROA | -38.1% | -33.2% | -13.0% | -11.4% | -7.9% | -7.3% | -11.9% | -10.8% | -8.5% | -16.8% | 1.8% | -10.6% | -9.2% | -20.3% | -12.1% | -10.2% | -9.9% | -14.0% | -13.5% | -11.0% | -1.2% |
| — | -353.8% | -10.0% | -6.1% | +7.8% | +56.6% | -759.2% | -1.5% | +7.4% | +16.9% | +114.8% | -4.5% | +7.2% | -44.3% | +9.9% | +8.0% | -750.8% | +21.2% | +6.4% | -3.9% | +89.0% | |
| ROIC | -40.5% | -36.1% | -13.9% | -11.8% | -9.5% | -9.4% | -10.7% | -10.6% | -10.3% | -11.4% | -4.0% | -11.7% | -13.1% | -22.4% | -11.7% | -9.4% | -10.1% | -12.7% | -12.7% | -10.3% | -17.1% |
| — | -282.9% | -30.1% | -11.1% | +8.1% | +17.4% | -164.7% | +8.9% | +20.9% | +48.9% | +65.6% | -24.4% | -29.9% | -76.3% | +8.1% | +8.5% | +41.0% | +28.9% | +8.1% | +5.7% | -36.3% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.18 | 0.23 | 0.21 | 0.18 | 0.16 | 0.15 | 0.14 | 0.13 | 0.12 | 0.12 | 0.10 | 0.10 | 0.09 | 0.09 | 0.12 | 0.11 | 0.01 | 0.00 | 0.15 | 0.13 | 0.00 |
| — | +55.2% | +48.2% | +44.7% | +31.0% | +30.8% | +44.4% | +20.9% | +28.8% | +29.9% | -14.8% | -4.0% | +1741.8% | +2317.4% | -20.8% | -13.4% | +135.3% | +12.9% | +3801.6% | +2000.8% | -8.1% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 6.93 | 4.82 | 6.19 | 6.93 | 7.76 | 7.99 | 6.94 | 7.32 | 7.29 | 6.59 | 9.19 | 7.16 | 8.97 | 10.90 | 7.28 | 7.98 | 8.03 | 9.61 | 6.93 | 7.98 | 9.58 |
| — | -39.7% | -10.8% | -5.4% | +6.3% | +21.1% | -24.6% | +2.3% | -18.6% | -39.5% | +26.3% | -10.2% | +11.7% | +13.3% | +5.1% | -0.1% | -16.2% | +24.4% | -25.8% | -33.8% | -38.6% | |
| Quick Ratio | 6.93 | 4.82 | 6.19 | 6.93 | 7.76 | 7.99 | 6.94 | 7.32 | 7.29 | 6.59 | 9.19 | 7.16 | 8.97 | 10.90 | 7.28 | 7.98 | 8.03 | 9.61 | 6.93 | 7.98 | 9.58 |
| — | -39.7% | -10.8% | -5.4% | +6.3% | +21.1% | -24.6% | +2.3% | -18.6% | -39.5% | +26.3% | -10.2% | +11.7% | +13.3% | +5.1% | -0.1% | -16.2% | +24.4% | -25.8% | -33.8% | -38.6% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -150.01 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 28 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ZNTL stock.
Zentalis Pharmaceuticals, Inc.'s current P/E is -1.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Zentalis Pharmaceuticals, Inc.'s business trajectory between earnings reports.